- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03780127
ZX008 Expanded Access Protocol
ZX008 Expanded Access Protocol - Dravet Syndrome Treatment Plan
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The treatment plan consists of an up to 24-month Treatment Period. Access is via application by your health care provider and available at one of the Expanded Access treatment centers. The dose of ZX008 for the duration of the Treatment Period will range from 0.2 mg/kg/day to a maximum of 0.8 mg/kg/day, not to exceed a total daily dose of 30 mg/day; for patients concurrently being prescribed stiripentol, the maximum will be 0.5mg/kg/day, not to exceed a total daily dose of 20 mg/day.
The fenfluramine US Expanded Access Program (US EAP) is available to full-time US Residents only.
Participation in the US EAP is limited to patients currently residing in the US. Residency in the US must be for the duration of participation in the US EAP. Drug may not be shipped outside the US.
Study Type
Expanded Access Type
- Treatment IND/Protocol
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient is male or female, age 2 years and older, inclusive as of Study Day 1.
- Patient is diagnosed with Dravet syndrome.
- Patient is experiencing convulsive seizures which are not controlled by current AEDs.
- Patient is receiving at least one AED and will remain on at least one AED for the duration of treatment.
- Patient has been approved for inclusion by Zogenix.
Exclusion Criteria:
- Patient requires or starts using an unacceptable or contraindicated concomitant medication.
- Patient has valvulopathy.
- Patient is at risk for pulmonary hypertension.
- Patient exclusion will be at the sole discretion of the Sponsor.
Study Plan
How is the study designed?
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Epilepsy, Generalized
- Epileptic Syndromes
- Disease
- Epilepsy
- Epilepsies, Myoclonic
- Syndrome
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Selective Serotonin Reuptake Inhibitors
- Fenfluramine
Other Study ID Numbers
- ZX008-1800
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dravet Syndrome
-
University Health Network, TorontoZogenix, Inc.Not yet recruiting
-
TakedaActive, not recruitingDravet Syndrome (DS)China, United States, Canada, France, Hungary, Australia, Poland, Spain, Japan, Belgium, Greece, Brazil, Serbia, Germany, Italy, Latvia, Netherlands, Russian Federation, Ukraine
-
TakedaRecruitingLennox Gastaut Syndrome (LGS) | Dravet Syndrome (DS)United States, China, Spain, France, Belgium, Australia, Brazil, Canada, Germany, Greece, Hungary, Italy, Japan, Latvia, Netherlands, Poland, Serbia, Mexico, Russian Federation, Ukraine
-
TakedaRecruitingDravet Syndrome (DS) | Lennox-Gastaut Syndrome (LGS)Spain
-
TakedaActive, not recruitingEpilepsy | Dravet Syndrome (DS) | Lennox-Gastaut Syndrome (LGS)United States, Canada, Australia, China, Israel, Poland, Spain, Portugal
-
Encoded TherapeuticsRecruiting
-
Boston Children's HospitalEncoded TherapeuticsRecruitingDravet SyndromeUnited States
-
Stoke Therapeutics, IncCompleted
-
Fondazione Policlinico Universitario Agostino Gemelli...IRCCS San RaffaeleEnrolling by invitation
-
Zogenix International Limited, Inc., a subsidiary...CompletedDravet SyndromeUnited States, United Kingdom, Spain, Belgium, Italy, Australia, Denmark, Germany, Canada, Japan, Netherlands, France
Clinical Trials on Fenfluramine Hydrochloride
-
Children's Hospital of Orange CountyRecruiting
-
University of California, Los AngelesAvailableDravet SyndromeUnited States
-
Zogenix International Limited, Inc., a subsidiary...CompletedDravet SyndromeUnited States, United Kingdom, Spain, Belgium, Italy, Australia, Denmark, Germany, Canada, Japan, Netherlands, France
-
Zogenix International Limited, Inc., a subsidiary...TerminatedDravet SyndromeUnited States
-
Zogenix International Limited, Inc., a subsidiary...CompletedDravet Syndrome | Seizure DisorderUnited States, United Kingdom, Australia, Belgium, Canada, Denmark, France, Germany, Italy, Japan, Spain
-
Elizabeth Anne ThieleZogenix International Limited, Inc., a subsidiary of Zogenix, Inc.Active, not recruitingPhotosensitive EpilepsyUnited States
-
Zogenix, Inc.Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.Active, not recruitingDravet Syndrome | Epileptic Encephalopathy | Lennox Gastaut SyndromeUnited States, Australia, Belgium, Canada, Denmark, France, Germany, Italy, Mexico, Netherlands, Poland, Spain, Sweden, United Kingdom
-
Zogenix International Limited, Inc., a subsidiary...CompletedDravet SyndromeUnited States, France, United Kingdom, Canada, Germany, Netherlands, Spain
-
Zogenix, Inc.RecruitingGeneralized Tonic Clonic Seizure | CDKL5 Deficiency Disorder | Epileptic Spasm | Refractory SeizuresUnited States, Japan, Germany, Netherlands, Portugal, Spain, Belgium, United Kingdom, Austria, Georgia, Israel, Ireland